© Reuters. File photo of the logo of Johnson and Johnson subsidiary Janssen Vaccines in Leiden, the Netherlands Mar 9, 2021. REUTERS/Piroschka van de Wouw/
AMSTERDAM, Aug 23 (Reuters) – Johnson & Johnson’s (NYSE:) Janssen division, which helped develop the single-dose COVID-19 vaccine, will shut down much of its vaccine research and development operations in the Netherlands, reported the newspaper De Telegraaf.
In an emailed response Wednesday, Johnson & Johnson confirmed plans to exit some vaccine research and development programs, which it said it initially disclosed in its second-quarter 2023 results.
“We also continually assess our global footprint, including that of the Netherlands, to ensure it meets our current and evolving scientific needs,” Johnson & Johnson said.
De Telegraaf reported that 2,500 people worked at Janssen in the Netherlands, a quarter of them in the section specializing in infectious diseases and vaccines.
It is not clear how many jobs were at risk.
(Reporting by Charlotte Van Campenhout and Toby Sterling. Editing in Spanish by Marion Giraldo)
2023-08-23 16:57:00
#JJs #Janssen #shut #part #vaccine #division #media #Reuters
